Antisense Therapeutics Limited (AU:PER) has released an update.
Percheron Therapeutics Limited has announced the appointment of Dr. Cathryn Clary as Chief Medical Advisor, adding her extensive experience in drug development and gene therapy, particularly in Duchenne muscular dystrophy, to the team. Dr. Clary’s role is set to bolster Percheron’s progress on their lead drug candidate, ATL1102, as they transition into a critical phase of clinical development. The company continues to focus on novel therapies for rare diseases, with ATL1102 currently undergoing an international phase IIb clinical trial for Duchenne Muscular Dystrophy.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
